As 2022 begins, the pandemic is still at the forefront of the healthcare industry. Recently, as COVID-19 case counts have risen dramatically around the world due to the highly infectious Omicron variant, new challenges are presenting:
- What is the best mitigation strategy?
- How do we protect the vulnerable?
- How and when should we test?
- Does this mean we are closer to a new "normal"?
Join A&M Healthcare Industry Group's Marthe Haverkamp, M.D., Ph.D, as she sits down with world-renowned virologist Ab Osterhaus, Ph.D., and vaccine expert Manon Cox, Ph.D., MBA, Chief Executive Officer and Co-Founder of NextWaveBio. They discuss the future of vaccines, the value of COVID-19 treatments, and the influence of Omicron on the pandemic: Is a relatively mild disease now a comparative advantage for the future?
Download the transcript
Subscribe to our Healthcare Industry Group Podcast:
Disruption in the ACA Market – Implications and Strategic Responses
June 11, 2025
In a recent article, A&M Healthcare Industry Group experts explore key policy changes, market dynamics, stakeholder implications and strategic actions for navigating the evolving landscape surrounding the Affordable Care Act marketplace.
The Effect of Trump’s Tariffs on the European Pharmaceutical and Biopharmaceutical Industry
June 9, 2025
As the U.S. considers imposing tariffs on European pharmaceutical imports, the ripple effects could
be felt across the global healthcare landscape.
FORMER FEDERAL HEALTH MINISTER PROFESSOR GREG HUNT JOINS ALVAREZ & MARSAL AUSTRALIA
May 27, 2025
Alvarez & Marsal appoints The Honourable Greg Hunt as a Senior Advisor bolstering its Healthcare and Public Sector advisories in support of maximizing sustainable value for clients.
Contract Research Organisations M&A Market
March 28, 2025
Rising cost pressures, stricter regulatory demands and advancements in emerging therapeutics are intensifying competition within the industry. These dynamics are fuelling the demand for greater efficiency in development lifecycles, creating significant opportunities for outsourced providers like Contract Research Organisations (CROs).
